• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

莫洛替尼与费德拉替尼治疗骨髓纤维化患者安全性的间接治疗比较

Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.

作者信息

Masarova Lucia, Verstovsek Srdan, Palandri Francesca, Mesa Ruben, Harrison Claire, Sajeev Gautam, Gorsh Boris, Simpson Ryan, Cho Sang, Wang Zhaohui, Ellis Catherine, Conlon Seán, Signorovitch James

机构信息

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

出版信息

Future Oncol. 2025 Jul;21(16):2077-2087. doi: 10.1080/14796694.2025.2511564. Epub 2025 Jun 6.

DOI:10.1080/14796694.2025.2511564
PMID:40476514
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12218749/
Abstract

AIM

To perform an indirect treatment comparison of safety outcomes between the Janus kinase (JAK) inhibitors momelotinib and fedratinib in patients with myelofibrosis.

METHODS

Adverse events (AEs) for JAK inhibitor - naive and - experienced populations occurring in ≥ 10% of patients treated with momelotinib (SIMPLIFY-1/SIMPLIFY-2/MOMENTUM) or fedratinib (JAKARTA/JAKARTA-2) in phase 2/3 trials were evaluated using matching-adjusted indirect comparisons.

RESULTS

Risk of any-grade or grade 3/4 anemia, diarrhea, nausea, and treatment-emergent AEs leading to dose reductions was lower with momelotinib in both populations; any-grade thrombocytopenia was also significantly less likely in JAK inhibitor - naive patients.

CONCLUSIONS

Momelotinib showed a favorable safety profile vs fedratinib, including significantly lower risks of key hematologic and gastrointestinal AEs - such as anemia, diarrhea, and nausea - over 24 weeks.

摘要

目的

对骨髓纤维化患者中，Janus激酶（JAK）抑制剂莫洛替尼和非达替尼的安全性结果进行间接治疗比较。

方法

使用匹配调整间接比较，评估在2/3期试验中，接受莫洛替尼（SIMPLIFY-1/SIMPLIFY-2/MOMENTUM）或非达替尼（JAKARTA/JAKARTA-2）治疗且≥10%的初治及经治患者中发生的不良事件（AE）。

结果

在这两类人群中，莫洛替尼导致的任何级别或3/4级贫血、腹泻、恶心以及导致剂量减少的治疗中出现的AE的风险均较低；在初治JAK抑制剂患者中，任何级别血小板减少症的发生可能性也显著更低。

结论

与非达替尼相比，莫洛替尼显示出良好的安全性，在24周内，关键血液学和胃肠道AE（如贫血、腹泻和恶心）的风险显著更低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/1e9d18406406/IFON_A_2511564_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/e28bc5f86f2d/IFON_A_2511564_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/5b71852f856c/IFON_A_2511564_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/1e9d18406406/IFON_A_2511564_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/e28bc5f86f2d/IFON_A_2511564_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/5b71852f856c/IFON_A_2511564_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90cd/12218749/1e9d18406406/IFON_A_2511564_F0003_B.jpg

相似文献

1
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.莫洛替尼与费德拉替尼治疗骨髓纤维化患者安全性的间接治疗比较
Future Oncol. 2025 Jul;21(16):2077-2087. doi: 10.1080/14796694.2025.2511564. Epub 2025 Jun 6.
2
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.莫洛替尼与帕西替尼治疗骨髓纤维化患者安全性及贫血转归的间接治疗比较
Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.
3
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.用莫洛替尼治疗的初治或经治JAK抑制剂的骨髓纤维化患者输血强度的纵向评估
Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):199-211. doi: 10.1016/j.clml.2024.10.001. Epub 2024 Oct 16.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
10
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物：网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.

本文引用的文献

1
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.Momelotinib 的长期安全性和生存获益：3 期随机对照临床试验的综合分析。
Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311.
2
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.莫米松（JAK1/JAK2/ACVR1 抑制剂）：作用机制、临床试验报告以及除骨髓纤维化之外的治疗前景。
Haematologica. 2023 Nov 1;108(11):2919-2932. doi: 10.3324/haematol.2022.282612.
3
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
4
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.口服JAK2/IRAK1抑制剂帕西替尼治疗骨髓纤维化患者的风险调整安全性分析。
EJHaem. 2022 Oct 20;3(4):1346-1351. doi: 10.1002/jha2.591. eCollection 2022 Nov.
5
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.骨髓增殖性肿瘤临床实践指南（第 3 版）. 2022 年 NCCN
J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046.
6
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.Fedratinib 治疗骨髓纤维化患者的安全性和疗效，Fedratinib 是一种选择性口服 Janus 激酶-2（JAK2）抑制剂，患者血小板计数低。
Br J Haematol. 2022 Jul;198(2):317-327. doi: 10.1111/bjh.18207. Epub 2022 Apr 27.
7
Momelotinib: an emerging treatment for myelofibrosis patients with anemia.莫雷洛替尼：治疗贫血性骨髓纤维化患者的新兴疗法。
J Hematol Oncol. 2022 Jan 19;15(1):7. doi: 10.1186/s13045-021-01157-4.
8
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10/L): Final Analysis of an Open-Label Phase 2 Study.鲁索替尼治疗骨髓纤维化且血小板计数低（50 - 100×10⁹/L）患者的安全性和有效性：一项开放标签2期研究的最终分析
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):336-346. doi: 10.1016/j.clml.2021.10.016. Epub 2021 Nov 2.
9
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.Janus 激酶抑制剂在骨髓纤维化中的疗效和耐受性：系统评价和网络荟萃分析。
Blood Cancer J. 2021 Jul 27;11(7):135. doi: 10.1038/s41408-021-00526-z.
10
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.非格司亭改善曾接受鲁索替尼治疗的骨髓纤维化患者的骨髓纤维化相关症状及健康相关生活质量：II期JAKARTA2试验的患者报告结局
Hemasphere. 2021 Apr 29;5(5):e562. doi: 10.1097/HS9.0000000000000562. eCollection 2021 May.